

KF Rabe reports financial for support for consultancy work from AstraZeneca, Chiesi, Novartis, MSD and GlaxoSmithKline, and grants from Altana, Novartis, AstraZeneca, MSD and Nycomed.

F Maltais reports financial support from Boehringer Ingelheim during the conduct of the study and, outside of the submitted work, financial support from Boehringer Ingelheim and GlaxoSmithKline for attendance at advisory boards, financial support from Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca and Novartis for speaking activities, and research support from Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, Nycomed and Novartis.

P295 EFFICACY AND SAFETY OF TIOTROPIUM/OLODATEROL IN PATIENTS WITH COPD BY ATS CATEGORY

10.1136/thoraxjnl-2016-209333.474

F Maltais reports financial support from Boehringer Ingelheim during the conduct of the study and, outside of the submitted work, financial support from Boehringer Ingelheim and GlaxoSmithKline for attendance at advisory boards, financial support from Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca and Novartis for speaking activities, and research support from Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, Nycomed and Novartis.

E Pizzichini has nothing to disclose.

L Grönke and F Voß are employees of Boehringer Ingelheim Pharma GmbH & Co. KG.

E Derom, outside of the submitted work, reports financial support from Boehringer Ingelheim, Actelion, AstraZeneca and Cipla for consultancy work, financial support from Chiesi, AstraZeneca and CSL Behring for advisory board attendance, and research support from Boehringer Ingelheim and GlaxoSmithKline.

P296 EFFECT OF TIOTROPIUM/OLODATEROL THERAPY ON COPD EXACERBATIONS IN THE TONADO® STUDIES

10.1136/thoraxjnl-2016-209333.475

E Derom, outside of the submitted work, reports financial support from Boehringer Ingelheim, Actelion, AstraZeneca and Cipla for consultancy work, financial support from Chiesi, AstraZeneca and CSL Behring for advisory board attendance, and research support from Boehringer Ingelheim and GlaxoSmithKline.

M Fležar has received personal fees from Boehringer Ingelheim and institutional financial support from Novartis.

L Grönke and F Voß are employees of Boehringer Ingelheim Pharma GmbH & Co. KG.

R Buhl reports financial support to his institution from Boehringer Ingelheim during the conduct of the study and, outside of the submitted work, financial support from Boehringer Ingelheim, AstraZeneca, Chiesi, Novartis, Teva, Roche and GlaxoSmithKline for attendance at advisory boards and speaking activities, and research support to his institution from Boehringer Ingelheim, GlaxoSmithKline, Novartis and Roche.

P297 LUNG-FUNCTION PROFILE BEFORE AND AFTER THE FIRST MODERATE TO SEVERE EXACERBATION DURING THE WISDOM STUDY

10.1136/thoraxjnl-2016-209333.476

E Wouters, outside of the submitted work, reports personal fees from AstraZeneca, GlaxoSmithKline, Novartis, Takeda, Pfizer and Boehringer Ingelheim, and grants from AstraZeneca, GlaxoSmithKline and Novartis.

H Magnussen received funding from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck, Novartis, Takeda and Roche to conduct clinical studies, and has spoken at meetings and is a member of advisory boards for these and other companies.

R Rodriguez-Roisin reports personal fees from AstraZeneca, Boehringer Ingelheim, Mylan, Pearl Therapeutics, Takeda, Teva and Ferrer, and grants and personal fees from Menarini and Almirall.

K Tetzlaff and S Bell are employees of Boehringer Ingelheim Pharma GmbH & Co. KG. PMAC reports financial support in the form of a grant from Boehringer Ingelheim to conduct the study and, outside of the submitted work, reports personal fees from GlaxoSmithKline, AstraZeneca, Takeda and Boehringer Ingelheim, and grants from GlaxoSmithKline and Takeda.

P298 TIOTROPIUM/OLODATEROL THERAPY PROVIDES SYMPTOMATIC BENEFITS IRRESPECTIVE OF PRIOR MAINTENANCE TREATMENT: POST HOC ANALYSES OF THE OTEMTO® STUDIES

10.1136/thoraxjnl-2016-209333.477

R Abrahams reports grants and personal fees from Boehringer Ingelheim during the conduct of the study and, outside of this work, grants and personal fees from GlaxoSmithKline and grants from AstraZeneca and Pearl Therapeutics.

GT Ferguson, during the conduct of the study, reports grants, personal fees and non-financial support from Boehringer Ingelheim and, outside the submitted work, grants, personal fees and non-financial support from Boehringer Ingelheim, personal fees from GlaxoSmithKline, grants and personal fees from Novartis, AstraZeneca, Pearl Therapeutics and Sunovion, and grants from Forest.

L Bjermer reports no conflicts of interest.

L Grönke and F Voß are employees of Boehringer Ingelheim Pharma GmbH & Co. KG.

D Singh reports other financial activities from Boehringer Ingelheim during the conduct of the study and, outside of the submitted work, grants and personal fees from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Glenmark, Johnson & Johnson, Merck, NAPP, Novartis, Pfizer, Takeda, Teva, Theravance and Verona, and personal fees from Genentech and SkyePharma.